For anyone watching a loved one decline with Alzheimer's, the frustrating reality has long been that the disease is diagnosed too late and treated too poorly. A detailed review now consolidates evidence that the brain's own cellular postal system—nanoscale particles called extracellular vesicles—is both a central villain in disease progression and a surprisingly promising therapeutic tool.
Extracellular vesicles (EVs) are lipid-membrane packets, typically 30–1000 nm in diameter, shed by virtually every cell type to shuttle proteins, RNA, lipids, and metabolites to neighboring and distant cells. In Alzheimer's disease, neurons, astrocytes, and microglia each release EVs loaded with amyloid-β oligomers and hyperphosphorylated tau, enabling these toxic aggregates to propagate across neural networks far more efficiently than diffusion alone would allow. Critically, disease-associated EV cargo signatures are detectable in blood, cerebrospinal fluid, and even urine, suggesting accessible windows for early diagnosis. On the therapeutic side, bioengineered EVs can be surface-modified with targeting ligands and loaded with therapeutic RNA or small molecules, potentially crossing the blood-brain barrier with greater efficiency and lower immunogenicity than synthetic nanoparticles.
This review arrives at a moment when the field is transitioning from descriptive biology toward translational application, making its critical accounting of obstacles especially valuable. The heterogeneity problem is non-trivial: EV populations from even a single biofluid contain dozens of subtypes with overlapping size and density ranges, confounding both biomarker interpretation and therapeutic dosing. Standardization of isolation methods—ultracentrifugation, size-exclusion chromatography, precipitation kits—remains a persistent barrier to reproducibility across labs. Most therapeutic EV studies are preclinical, conducted in rodent models that imperfectly recapitulate human Alzheimer's pathology. Immune clearance in vivo and unpredictable biodistribution further complicate translation. Taken together, this is an intellectually rich and rapidly maturing area, but the gap between mechanistic insight and clinical utility remains wide. Adults invested in brain longevity should watch EV-based biomarker panels as the nearest-term deliverable.